{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:33:35Z","timestamp":1784194415238,"version":"3.55.0"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A total of 15,480 Gram-positive pathogens were collected from 89 sites in the United States, Europe, the Asia-Pacific region, and Latin America in 2010. Telavancin was active against indicated\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml), vancomycin-susceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterococcus faecalis<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/0.5 \u03bcg\/ml), and beta-hemolytic (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml) and viridans group streptococcus (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.03\/0.06 \u03bcg\/ml) isolates. These MIC results showed potency for telavancin equal to or greater than that of comparators. These\n            <jats:italic>in vitro<\/jats:italic>\n            data confirm a continued potent activity of telavancin when tested against contemporary Gram-positive clinical isolates.\n          <\/jats:p>","DOI":"10.1128\/aac.00011-12","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T05:22:29Z","timestamp":1334640149000},"page":"3999-4004","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents"],"prefix":"10.1128","volume":"56","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 8th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_3_2","unstructured":"Clinical and Laboratory Standards Institute. 2011. M100-S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-07"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dkn124","article-title":"In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative","volume":"62","author":"Draghi DC","year":"2008","unstructured":"DraghiDC . 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116\u2013121.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_6_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). January 2011. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3 January 2011. European Society of Clinical Microbiology and Infectious Diseases Basel Switzerland. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.09.017"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr073"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky JA","year":"2011","unstructured":"KarlowskyJA AdamHJ PoutanenSM HobanDJ ZhanelGG. 2011. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study. Diagn. Microbiol. Infect. Dis. 69:342\u2013347.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00742-09"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-07"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00301-10"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.05.012"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.03.009"},{"key":"e_1_3_2_17_2","unstructured":"Theravance. 2009. Vibativ package insert. Theravance South San Francisco CA. http:\/\/www.vibativ.com."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00011-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00011-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:09:48Z","timestamp":1645452588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00011-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1128\/AAC.00011-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00011-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"2012-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}